Application of oleanane-type triterpene derivatives in the preparation of cardiovascular disease drugs

Through microbial transformation technology, the structure of betaliphinic acid was modified to obtain oleanoyl triterpene derivatives, which solved the problem of fewer reaction sites of pentacyclic triterpenes and provided a protective effect on cardiomyocyte damage. Provides new active ingredients for the development of cardiovascular disease drugs.

CN116077508BActive Publication Date: 2024-12-03WUHAN HAOZE INFORMATION TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211106110.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-09
Publication Date
2024-12-03
Estimated Expiration
2042-09-09

AI Technical Summary

Technical Problem

Due to its special structural characteristics, pentacyclic triterpene compounds such as betaliphinic acid have few reaction sites on the parent nucleus, making it difficult to obtain derivatives with modifications such as hydroxyl groups and carbonyl groups, which limits the reaction sites and the structure of derivatives for chemical structural modifications. Diversity, which in turn affects drug development.

Method used

Using microbial transformation technology, the betalipinate was transformed using the strain of Cypermia strain, and the active groups such as hydroxyl and carbonyl were successfully introduced into the parent nucleus, which was converted into oleanoalkane triterpene derivatives, which were used to prepare cardiovascular diseases. drug.

Benefits of technology

Oleanoalkane triterpene derivatives with significant protective activity for cardiomyocyte damage were obtained, providing new drug components, solving the problem of fewer reaction sites for triterpenes, and enhancing the biological activity and structural diversity of drugs. sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure BDA0003840572620000011
    Figure BDA0003840572620000011
  • Figure BDA0003840572620000021
    Figure BDA0003840572620000021
Patent Text Reader

Abstract

The present invention belongs to the field of medical technology, and discloses the use of an oleanane-type triterpene derivative in the preparation of cardiovascular disease drugs. The present invention utilizes microbial transformation technology to transform betulinic acid into a novel oleanane-type triterpene derivative having a carbonyl group at position 3, a hydroxyl group at position 7β, a hydroxyl group at position 15α, a hydroxyl group at position 29, and a lactone substitution structure at position 19β and a lactone substitution structure at position 28β. The compound has good myocardial cell protection activity, can be used as an active ingredient for treating myocardial ischemia-reperfusion injury, and can be used to prepare drugs for treating myocardial ischemia-reperfusion injury, through in vitro myocardial cell injury protection tests and myocardial cell ischemia-reperfusion tests.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine, and specifically relates to the application of an oleanane-type triterpene derivative in the preparation of cardiovascular disease drugs. Background Art

[0002] With the improvement of living standards and the aging of the population, and under the influence of social and environmental factors, the incidence of cardiovascular diseases has increased year by year and has become one of the diseases with the highest mortality rate in humans. In the occurrence and development of various cardiovascular diseases such as myocardial infarction and ischemia-reperfusion injury, myocardial cell damage is often accompanied, and then cell apoptosis occurs, causing cardiovascular dysfunction. Myocardial ischemia and oxidative stress are important factors in the occurrence of cardiovascular diseases.

[0003] Betulinic acid, also known as betulinic acid, is a lupine-type pentacyclic triterpenoid compound, mainly derived from the bark of birch, and also found in plants such as apple, Quisqualis, Vitex negundo and boxwood. Modern pharmacological studies have found that betulinic acid has biological activities such as anti-tumor, anti-viral and anti-inflammatory, among which it is famous for anti-melanoma. As an oxidation product of betulinic acid, betulinic acid is an important intermediate in medicinal chemistry research. Studies have found that the anti-HIV activity of betulinic acid products is enhanced after structural modification. In terms of chemical structure modification, the chemical synthesis derivatives of betulinic acid have been extensively studied in anti-tumor, and the sites of chemical structure modification are mainly the carbonyl group at position 3 and the carboxyl group at position 28 of betulinic acid. However, due to the particularity of the structure of pentacyclic triterpenoid compounds, the parent nucleus lacks active groups and has few reaction sites. It is difficult to obtain derivatives with modifications such as hydroxyl and carbonyl groups on the parent nucleus using conventional chemical reaction methods. Therefore, the reaction sites of chemical structure modification of betulinic acid and the structural diversity of derivatives are severely limited. Microbial transformation is the process of using enzymes in microbial cells to modify the structure of substrates and transform them into other compounds. The special intracellular or extracellular enzymes produced by fermentative fungi, actinomycetes and other microorganisms during their growth can not only catalyze their own substances, but also catalyze specific chemical reactions for foreign compounds, such as hydrolysis, oxidation, reduction, cleavage, skeleton rearrangement, etc., thus becoming a powerful tool for structural modification and transformation of complex natural products. Our research group has long been engaged in the research of microbial transformation of natural active ingredients, especially the microbial transformation of natural active triterpenes. The transformation of common triterpenes from natural sources (including dammarane-type, cycloartane-type, ursane-type, oleanane-type triterpenes and lupetane-type, etc.) was studied using a variety of microorganisms. It was found that the microbial enzyme system can selectively catalyze multiple non-chemical reaction active sites on the triterpene mother nucleus, thereby obtaining derivatives with chemically active groups such as hydroxyl and carbonyl groups on the mother nucleus (Journal of natural products 2021, 84: 2664-2674; Phytochemistry 2021, 182: 112608; Natural Product Research 2021, 35(16): 2685-2690; Phytochemistry 2019, 166: 112076; Planta Medica 2019, 85(1): 56-61). On the one hand, microbial transformation products can obtain derivatives with stronger biological activity that can be directly used in drug research and development. On the other hand, the newly introduced chemically active groups on the parent nucleus after microbial transformation increase the sites for chemical modification and transformation, solving the problem of few reaction sites for the organic chemical preparation of triterpenoid derivatives. Summary of the invention

[0004] The purpose of the present invention is to provide an application of an oleanane-type triterpene derivative or a pharmaceutically acceptable salt thereof in the preparation of a cardiovascular disease drug, which can prevent or treat cardiovascular diseases.

[0005] The present invention provides an application of an oleanane-type triterpene derivative having a structure of formula I or a pharmaceutically acceptable salt thereof in the preparation of a cardiovascular disease drug.

[0006]

[0007] The compound with the structural formula I is a new oleanane-type triterpene derivative disclosed for the first time in the present invention.

[0008] The present invention also provides a method for preparing the above-mentioned oleanane-type triterpene derivatives, comprising the following steps:

[0009] 1) fermenting and culturing a microorganism, adding betulinic acid to a culture medium, then performing transformation culture, removing mycelium to obtain a fermentation liquid, wherein the microorganism is a strain of the genus Cichorium;

[0010] 2) extracting the fermentation broth, and evaporating the extract to obtain a crude conversion extract;

[0011] 3) The crude extract was subjected to silica gel column chromatography with dichloromethane:methanol as the mobile phase for gradient elution. The fractions were collected and analyzed by TLC to obtain 5 components.

[0012] 4) Purifying the components by reverse phase high performance liquid chromatography to obtain oleanane type triterpene derivatives.

[0013] Preferably, in step 1), the transformation culture temperature is 30° C., the shaking speed is 130 rpm, and the culture time is 120 hours.

[0014] Preferably, in step 2), the extraction solvent is dichloromethane.

[0015] Preferably, in step 3), the gradient elution conditions are dichloromethane:methanol 100:0-50:1-30:1-20:1-10:1.

[0016] Furthermore, the cardiovascular disease includes cardiovascular disease caused by myocardial cell apoptosis, heart failure or myocardial ischemia-reperfusion injury.

[0017] Furthermore, the cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease or chronic heart failure.

[0018] Furthermore, the medicine also contains pharmaceutically acceptable excipients.

[0019] Furthermore, the pharmaceutically acceptable excipient is one or more of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant, an adsorption carrier and a lubricant.

[0020] Compared with the prior art, the present invention utilizes microbial transformation technology to convert lupine-type triterpene betulinic acid into oleanane-type triterpene, and simultaneously successfully performs structural modifications on non-chemically reactive sites 7, 15 and 29 on the parent nucleus, introduces reactive reactive groups hydroxyl groups, and obtains an oleanane-type triterpene derivative having significant protective activity against myocardial cell damage, which can be used as an active ingredient in drugs for treating cardiovascular diseases and has a wide range of uses.

[0021] DETAILED DESCRIPTION

[0022] To further illustrate the present invention, the preparation process of an oleanane-type triterpene derivative provided by the present invention and its application in cardiovascular disease drugs are described in detail below in conjunction with examples.

[0023] Example 1: Preparation of a compound having the structural formula I

[0024] The present invention adopts a microbial transformation method, using betulinic acid as a raw material, and preparing the compound of the present invention through fermentation, extraction, separation and other steps. The strain of Circinella can be purchased from the Microbial Culture Collection Management Center of the Chinese Academy of Sciences (CGMCC), and a potato culture medium is selected and stored in a refrigerator at 4°C on a solid slant culture medium.

[0025] Taking Circinella muscae CGMCC 3.2695 as an example, the process for preparing the compound of formula I is as follows:

[0026] 1) Fermentation, transformation and extraction

[0027] Circinella muscae CGMCC 3.2695 was inoculated into two 250 mL triangular flasks (containing 100 mL potato culture medium) as seed liquid. After 1 day of shaking culture at 130 rpm and 30 ° C on a shaker, when the mycelium is in a vigorous growth period, 1 mL of seed liquid was taken with a sterile pipette and added to 20 1000 mL shake flasks (containing 400 mL potato culture medium). After 1 day of shaking culture, 20 mg of betulinic acid (0.2 mL, 100 mg / mL DMSO solution) was added to each shake flask, and 400 mg of substrate was used in total. The transformation was continued for 5 days under the same conditions, the fermentation broth was filtered, the mycelium was filtered out, and the filtrate was extracted 3 times with an equal volume of dichloromethane. The extract was concentrated to dryness under reduced pressure to obtain a crude extract of about 0.52 g of the transformant.

[0028] 2) Silica gel column chromatography separation

[0029] The crude extract was separated by silica gel column chromatography using a gradient elution of dichloromethane:methanol (100:0, 50:1, 30:1, 20:1, 10:1). The fractions were collected and combined after TLC analysis to obtain combined components AE.

[0030] 3) Reverse-phase HPLC purification

[0031] The combined fraction C was purified by reverse phase high performance liquid chromatography. The preparation conditions were semi-preparative chromatography column YMC ODSA-5μm, 10.0×250mm, acetonitrile-water (55:45, V / V), flow rate 2.5mL / min, detection wavelength 203nm. The conversion product with the structural formula of formula I was obtained, and its mass spectrum and spectral data are shown below.

[0032] Compound I: 3-oxo-7β,15α,29-trihydroxyoleanan-28β,19β-lactone; melting point 304–306℃; +37.5°(c=0.1, MeOH); Main absorption peak of infrared spectrum (KBr)ν max :3551,3032,2968,1734,1695,1381,1226,1048cm -1 ; High resolution mass spectrum m / z 525.3192[M+Na] + (calcd.525.3187 for C 30 H 46 O6Na); the H NMR and C NMR data are shown in Table 1.

[0033] Table 1. Attribution of H NMR and C NMR data of compound Ⅰ (deuterated chloroform)

[0034]

[0035]

[0036] The above results show that the structure of the obtained compound is correct.

[0037] Example 2 Protective activity of compound I against myocardial cells damaged by hydrogen peroxide

[0038] (1) Experimental Materials

[0039] CO2 incubator (Jouan IGO150); microplate reader (Bio-TEK ELx800); fluorescence inverted microscope (OlympusIX51); MTT cell proliferation and cytotoxicity detection kit (Biyuntian Biotechnology Research Institute), DMEM high glucose medium (Gibcol BRL), fetal bovine serum, dimethyl sulfoxide (DMSO), trypsin (Shanghai Bioengineering Co., Ltd.), 30% hydrogen peroxide (H2O2) (Tianjin Ruijinte Chemical Co., Ltd.), H9c2 cells (Institute of Oncology, Chinese Academy of Medical Sciences).

[0040] (2) Experimental methods

[0041] The MTT method was used to determine the effects of each test compound on the activity of H9c2 cells damaged by H2O2: the cells were counted after trypsin digestion, and the cell density of the cell suspension was adjusted to 5×10 4 / mL, add 200μL to each well of a 96-well culture plate, and culture in a 5% CO2, 37℃ constant temperature CO2 incubator for 12h. After the cells adhere to the wall, they are divided into groups for treatment: control group, model group (H2O2600μmol / L injury for 6h), model + test compound (10, 20, 40μM) group, and positive control group pinacidil. The final volume of each well is 200μL, and 3 parallels are set for each concentration. After 24h of drug treatment, add 10μL of MTT solution (5mg / mL, i.e. 0.5% MTT) to each well and continue to culture for 4h. Measure the absorbance of each well at 490nm with an enzyme reader, and calculate the cell survival rate: cell survival rate = OD value of the drug group / OD value of the control group.

[0042] (3) Experimental results

[0043] According to the test results of MTT method, the survival rate of H9c2 cells damaged by H2O2 by compound I was calculated and the results are shown in Table 2.

[0044] Table 2 Effects of test compounds on the survival rate of H9c2 cells damaged by H2O2

[0045]

[0046] (Compared with the control group, # P<0.05; compared with the model group, * P<0.05, ** P<0.01)

[0047] Compared with the control group, the cell survival rate of the H2O2-treated group was significantly reduced, indicating that the cell model was successfully established. Compared with the H2O2-treated group, compound I can significantly increase the cell survival rate, indicating that compound I has a significant myocardial cell protective effect, and shows a good dose-dependent relationship within a certain dose range, and can be used as an active ingredient for the treatment of myocardial infarction, coronary atherosclerotic heart disease, and chronic heart failure.

[0048] Example 3 Protective effect of compound I of the present invention on myocardial cell ischemia-reperfusion injury

[0049] 1) Experimental Materials

[0050] CO2 incubator (Jouan IGO150); microplate reader (Bio-TEK ELx800); fluorescence inverted microscope (OlympusIX51); MTT cell proliferation and cytotoxicity detection kit (Biyuntian Biotechnology Research Institute), DMEM high glucose medium (Gibcol BRL), fetal bovine serum, dimethyl sulfoxide (DMSO), trypsin (Shanghai Bioengineering Co., Ltd.), H9c2 cells (Institute of Oncology, Chinese Academy of Medical Sciences).

[0051] Test samples: betulinic acid and compound I synthesized in Example 1, with a purity of more than 95%, and each compound was dissolved in DMSO and then diluted.

[0052] 2) Experimental methods

[0053] H9c2 cells in the logarithmic growth phase were cultured in DMEM containing 10% calf serum and 1% penicillin-streptomycin double antibody solution, and the cell concentration was adjusted to 5×10 4 / mL, inoculated into 96-well culture plates, replaced with new sugar-free and serum-free fresh culture medium after about 24 hours, and added with compounds, placed in an anaerobic workstation for hypoxia damage for 1 hour, taken out, added with sugar and serum, and cultured for another 24 hours. After 24 hours, the cell viability of each well was detected by MTT staining.

[0054] 3) Experimental results

[0055] According to the test results of MTT method, the effect of compound I on the survival rate of H9c2 cells injured by ischemia-reperfusion was calculated and the results are shown in Table 3.

[0056] Table 3 Effects of test samples on the survival rate of H9c2 cells injured by ischemia-reperfusion

[0057]

[0058] (Compared with the control group, # P<0.05; compared with the model group, * P<0.05, ** P<0.01)

[0059] The results showed that compared with the model group, the survival rate of cardiomyocytes could be significantly increased after treatment with different concentrations of compound I, indicating that compound I of the present invention can effectively protect H9c2 cardiomyocytes from damage caused by hypoxia / reoxygenation, and has a certain dose dependence, and can be used as an active ingredient in drugs for the treatment of myocardial infarction, coronary atherosclerotic heart disease, and chronic heart failure.

[0060] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of an oleanane-type triterpene compound having a structural formula as shown in Formula I or a pharmaceutically acceptable salt thereof as the sole active ingredient in the preparation of a drug for treating cardiovascular diseases, , The cardiovascular disease is myocardial ischemia-reperfusion injury.

2. The use according to claim 1, characterized in that: The medicine also contains pharmaceutically acceptable excipients.

3. The use according to claim 2, characterized in that: The pharmaceutically acceptable excipient is one or more of a diluent, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant and a lubricant.